To determine if there were significant differences in mutational profiles between HER2-positive IBC and HER2-positive non-IBC, we compared our results against a cohort of TCGA patients with HER2-positive breast cancer (n = 131, S4 Table) [36]. This evidence concerns the gene ERBB2 and breast carcinoma.